KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Non-Current Liabilities: 2017-2024

Historic Total Non-Current Liabilities for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $3.0 billion.

  • Moderna's Total Non-Current Liabilities fell 29.89% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 29.89%. This contributed to the annual value of $3.0 billion for FY2024, which is 31.09% down from last year.
  • Latest data reveals that Moderna reported Total Non-Current Liabilities of $3.0 billion as of FY2024, which was down 31.09% from $4.3 billion recorded in FY2023.
  • Moderna's Total Non-Current Liabilities' 5-year high stood at $10.4 billion during FY2021, with a 5-year trough of $3.0 billion in FY2024.
  • In the last 3 years, Moderna's Total Non-Current Liabilities had a median value of $4.3 billion in 2023 and averaged $4.6 billion.
  • As far as peak fluctuations go, Moderna's Total Non-Current Liabilities surged by 1,051.58% in 2020, and later crashed by 36.83% in 2022.
  • Yearly analysis of 5 years shows Moderna's Total Non-Current Liabilities stood at $4.8 billion in 2020, then soared by 118.90% to $10.4 billion in 2021, then slumped by 36.83% to $6.6 billion in 2022, then crashed by 34.61% to $4.3 billion in 2023, then crashed by 31.09% to $3.0 billion in 2024.